...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases
【24h】

Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases

机译:用于检测炎症性肠病患者血清中CUZD1自身抗体的新型免疫测定

获取原文
获取原文并翻译 | 示例

摘要

Background: Pancreatic autoantibodies (PABs) are detected in patients with inflammatory bowel disease (IBD). Their prevalence is higher in Crohn's disease (CrD) than in ulcerative colitis (UC). Glycoprotein 2 (GP2) and, more recently, CUB and zona pellucida-like domain-containing protein 1 (CUZD1) have been identified as target auto-antigens of PAB. The clinical utility of CUZD1 autoantibodies has only recently been assessed by indirect immunofluorescence (IIF) assays. In this study, we developed and validated novel immunoassays for the detection of CUZD1 autoantibodies.
机译:背景:胰腺肠道疾病(IBD)患者检测到胰腺自身抗体(PAB)。 克罗恩病(CRD)患病率高于溃疡性结肠炎(UC)。 糖蛋白2(GP2)和更近,幼崽和Zona Pellucida样结构域蛋白1(CuzD1)已被鉴定为PAB的靶自抗原。 CuzD1自身抗体的临床效用最近仅通过间接免疫荧光(IIF)测定来评估。 在这项研究中,我们开发和验证了用于检测CuzD1自身抗体的新型免疫测定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号